Prostacyclin inhibits IFN-γ-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner

Journal of Immunology

Volumn 183, Issue 11, 2009, Pages 6981-6988

  Strassheim, Derek ^a   Riddle, Suzzette R ^a   Burke, Danielle L ^a   Geraci, Mark W ^a   Stenmark, Kurt R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GAMMA INTERFERON; HISTONE ACETYLTRANSFERASE; ILOPROST; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTACYCLIN; PROTEIN P300; RANTES; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE; DRUG DERIVATIVE; HISTONE ACETYLTRANSFERASE PCAF; SMALL INTERFERING RNA; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPOPROSTENOL; GENE EXPRESSION REGULATION; HUMANS; ILOPROST; IMMUNOPRECIPITATION; INTERFERON-GAMMA; MONOCYTES; P300-CBP TRANSCRIPTION FACTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 73349114919     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901045     Document Type: Article

References (55)

1. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
2. Deo, R., A. Khera, D. K. McGuire, S. A. Murphy, P. Meo Neto Jde, D. A. Morrow, and J. A. de Lemos. 2004. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 44: 1812-1818.
3. Schober, A. 2008. Chemokines in vascular dysfunction and remodeling. Arterioscler. Thromb. Vasc. Biol. 28: 1950-1959.
4. Damas, J. K., K. Otterdal, A. Yndestad, H. Aass, N. O. Solum, S. S. Froland, S. Simonsen, P. Aukrust, and A. K. Andreassen. 2004. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110: 999-1005.
5. Dorfmuller, P., F. Perros, K. Balabanian, and M. Humbert. 2003. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22: 358-363.
6. Daley, E., C. Emson, C. Guignabert, R. de Waal Malefyt, J. Louten, V. P. Kurup, C. Hogaboam, L. Taraseviciene-Stewart, N. F. Voelkel, M. Rabinovitch, et al. 2008. Pulmonary arterial remodeling induced by a Th2 immune response. J. Exp. Med. 205: 361-372.
7. Ikeda, Y., Y. Yonemitsu, C. Kataoka, S. Kitamoto, T. Yamaoka, K. Nishida, A. Takeshita, K. Egashira, and K. Sueishi. 2002. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am. J. Physiol. 283: H2021-H2028.
8. Ito, T., T. Okada, H. Miyashita, T. Nomoto, M. Nonaka-Sarukawa, R. Uchibori, Y. Maeda, M. Urabe, H. Mizukami, A. Kume, et al. 2007. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ. Res. 101: 734-741.
9. Steiner, M. K., O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman. 2009. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104: 236-244.
10. Song, Y., L. Coleman, J. Shi, H. Beppu, K. Sato, K. Walsh, J. Loscalzo, and Y. Y. Zhang. 2008. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am. J. Physiol. 295: H677-H690.
11. Egan, K. M., J. A. Lawson, S. Fries, B. Koller, D. J. Rader, E. M. Smyth, and G. A. Fitzgerald. 2004. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957.
12. Badesch, D. B., V. V. McLaughlin, M. Delcroix, C. D. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst. 2004. Prostanoid therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43: 56S-61S.
13. Baker, S. E., and R. H. Hockman. 2005. Inhaled iloprost in pulmonary arterial hypertension. Ann. Pharmacother. 39: 1265-1274. (Pubitemid 40943180)
14. Ito, T., T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. 2007. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension 50: 531-536. (Pubitemid 47312240)
15. Katsushi, H., N. Kazufumi, F. Hideki, M. Katsumasa, M. Hiroshi, K. Kengo, D. Hiroshi, S. Nobuyoshi, E. Tetsuro, M. Hiromi, and O. Tohru. 2004. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ. J. 68: 227-231.
16. Idzko, M., H. Hammad, M. van Nimwegen, M. Kool, N. Vos, H. C. Hoogsteden, and B. N. Lambrecht. 2007. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J. Clin. Invest. 117: 464-472. (Pubitemid 46203975)
17. + Th2 cells into the airways in a mouse model of asthma. J. Immunol. 179: 6193-6203.
18. Goya, K., M. Otsuki, X. Xu, and S. Kasayama. 2003. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 52: 192-198.
19. Di Renzo, M., D. Pieragalli, S. Meini, V. De Franco, G. Pompella, A. Auteri, and A. L. Pasqui. 2005. Iloprost treatment reduces TNF-α production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot. Essent. Fatty Acids 73: 405-410.
20. Raychaudhuri, B., A. Malur, T. L. Bonfield, S. Abraham, R. J. Schilz, C. F. Farver, M. S. Kavuru, A. C. Arroliga, and M. J. Thomassen. 2002. The prostacyclin analogue treprostinil blocks NFκB nuclear translocation in human alveolar macrophages. J. Biol. Chem. 277: 33344-33348. (Pubitemid 34984857)
21. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J. Immunol. 178: 702-710.
22. Itoh, T., N. Nagaya, H. Ishibashi-Ueda, S. Kyotani, H. Oya, F. Sakamaki, H. Kimura, and N. Nakanishi. 2006. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 11: 158-163. (Pubitemid 43356895)
23. Kimura, H., O. Okada, N. Tanabe, Y. Tanaka, M. Terai, Y. Takiguchi, M. Masuda, N. Nakajima, K. Hiroshima, H. Inadera, et al. 2001. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164: 319-324.
24. Kitamoto, S., and K. Egashira. 2003. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert Rev. Cardiovasc. Ther. 1: 393-400.
25. Roque, M., W. J. Kim, M. Gazdoin, A. Malik, E. D. Reis, J. T. Fallon, J. J. Badimon, I. F. Charo, and M. B. Taubman. 2002. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler. Thromb. Vasc. Biol. 22: 554-559. (Pubitemid 34408733)
26. Werle, M., U. Schmal, K. Hanna, and J. Kreuzer. 2002. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc. Res. 56: 284-292. (Pubitemid 35223499)
27. Selzman, C. H., S. A. Miller, M. A. Zimmerman, F. Gamboni-Robertson, A. H. Harken, and A. Banerjee. 2002. Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am. J. Physiol. 283: H1455-H1461.
28. Schepers, A., D. Eefting, P. I. Bonta, J. M. Grimbergen, M. R. de Vries, V. van Weel, C. J. de Vries, K. Egashira, J. H. van Bockel, and P. H. Quax. 2006. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 26: 2063-2069.
29. McLaren, J. E., and D. P. Ramji. 2008. Interferon γ: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 20: 125-135.
30. Borden, E. C., G. C. Sen, G. Uze, R. H. Silverman, R. M. Ransohoff, G. R. Foster, and G. R. Stark. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6: 975-990.
31. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7: 454-465. (Pubitemid 46834848)
32. Waiboci, L. W., C. M. Ahmed, M. G. Mujtaba, L. O. Flowers, J. P. Martin, M. I. Haider, and H. M. Johnson. 2007. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J. Immunol. 178: 5058-5068.
33. Strassheim, D., J. Y. Kim, J. S. Park, S. Mitra, and E. Abraham. 2005. Involvement of SHIP in TLR2-induced neutrophil activation and acute lung injury. J. Immunol. 174: 8064-8071. (Pubitemid 40806317)
34. Delgado, M., and D. Ganea. 2000. Inhibition of IFN-γ-induced Janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J. Immunol. 165: 3051-3057.
35. Abramovitz, M., M. Adam, Y. Boie, M. Carriere, D. Denis, C. Godbout, S. Lamontagne, C. Rochette, N. Sawyer, N. M. Tremblay, et al. 2000. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483: 285-293.
36. Fujita, M., R. J. Mason, C. Cool, J. M. Shannon, N. Hara, and K. A. Fagan. 2002. Pulmonary hypertension in TNF-α-overexpressing mice is associated with decreased VEGF gene expression. J. Appl. Physiol. 93: 2162-2170.
37. Eddahibi, S., A. Chaouat, L. Tu, C. Chouaid, E. Weitzenblum, B. Housset, B. Maitre, and S. Adnot. 2006. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3: 475-476.
38. Valente, A. J., J. F. Xie, M. A. Abramova, U. O. Wenzel, H. E. Abboud, and D. T. Graves. 1998. A complex element regulates IFN-γ-stimulated monocyte chemoattractant protein-1 gene transcription. J. Immunol. 161: 3719-3728.
39. Varinou, L., K. Ramsauer, M. Karaghiosoff, T. Kolbe, K. Pfeffer, M. Muller, and T. Decker. 2003. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-γ-dependent innate immunity. Immunity 19: 793-802.
40. Fetalvero, K. M., M. Shyu, A. P. Nomikos, Y. F. Chiu, R. J. Wagner, R. J. Powell, J. Hwa, and K. A. Martin. 2006. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am. J. Physiol. 290: H1337-H1346.
41. Sands, W. A., and T. M. Palmer. 2008. Regulating gene transcription in response to cyclic AMP elevation. Cell. Signal. 20: 460-466.
42. Brysha, M., J. G. Zhang, P. Bertolino, J. E. Corbin, W. S. Alexander, N. A. Nicola, D. J. Hilton, and R. Starr. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon γ signal transduction in vitro and in vivo. J. Biol. Chem. 276: 22086-22089.
43. Jaffar, Z., K. S. Wan, and K. Roberts. 2002. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 169: 5997-6004.
44. 2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J. Leukocyte Biol. 81: 809-817.
45. Arehart, E., J. Stitham, F. W. Asselbergs, K. Douville, T. MacKenzie, K. M. Fetalvero, S. Gleim, Z. Kasza, Y. Rao, L. Martel, et al. 2008. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102: 986-993.
46. Biscetti, F., E. Gaetani, A. Flex, G. Straface, G. Pecorini, F. Angelini, E. Stigliano, T. Aprahamian, R. C. Smith, J. J. Castellot, and R. Pola. 2009. Peroxisome proliferator-activated receptor α is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J. Vasc. Res. 46: 103-108.
47. Falcetti, E., D. M. Flavell, B. Staels, A. Tinker, S. G. Haworth, and L. H. Clapp. 2007. IP receptor-dependent activation of PPARγ by stable prostacyclin analogues. Biochem. Biophys. Res. Commun. 360: 821-827.
48. He, T., T. Lu, L. V. d'Uscio, C. F. Lam, H. C. Lee, and Z. S. Katusic. 2008. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ. Res. 103: 80-88.
49. Lin, H., J. L. Lee, H. H. Hou, C. P. Chung, S. P. Hsu, and S. H. Juan. 2008. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J. Cell. Physiol. 214: 434-441.
50. Niwano, K., M. Arai, N. Koitabashi, S. Hara, A. Watanabe, K. Sekiguchi, T. Tanaka, T. Iso, and M. Kurabayashi. 2006. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26: 1036-1042.
51. Kalkhoven, E. 2004. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 68: 1145-1155.
52. Chen, L. F., S. A. Williams, Y. Mu, H. Nakano, J. M. Duerr, L. Buckbinder, and W. C. Greene. 2005. NF-κB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25: 7966-7975.
53. 1 inhibits IL-6-induced MCP-1 expression by interfering specifically in IL-6-dependent ERK1/2, but not STAT3, activation. Biochem J. 412: 65-72.
54. Sands, W. A., H. D. Woolson, G. R. Milne, C. Rutherford, and T. M. Palmer. 2006. Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol. Cell. Biol. 26: 6333-6346.
55. Machado, F. S., J. E. Johndrow, L. Esper, A. Dias, A. Bafica, C. N. Serhan, and J. Aliberti. 2006. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12: 330-334.